Biotech · Private company
Graybug Vision
Track this companyFree. Adds Graybug Vision to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- AfliberceptPhase 2 · Neovascular Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Drug: GB-102Phase 2 · Neovascular Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- GB-102Phase 2 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- GB-102Phase 1 · Neovascular Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMDPHASE2 · COMPLETED · started Sep 26, 2019ClinicalTrials.gov NCT03953079 · fetched Nov 12, 2026
- A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein OcclusionPHASE2 · COMPLETED · started Sep 11, 2019ClinicalTrials.gov NCT04085341 · fetched Nov 12, 2026
- A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular DegenerationPHASE1 · COMPLETED · started Aug 29, 2017ClinicalTrials.gov NCT03249740 · fetched Nov 12, 2026